2015 Press/Media Releases:

Phase 3 Data Supporting Rayaldee™ As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings

MIAMI – March 27, 2015--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK), today announced the presentation of additional phase 3 clinical data in a poster at the National Kidney Foundation's Spring Clinical Meetings on March 27-28th, 2015 in Dallas, Texas, that will include data for 429 patients completing up to twelve months of treatment in OPKO's phase 3 trials for Rayaldee as a treatment for secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. The data to be presented will highlight the unexpected finding that responses to Rayaldee treatment are as good in patients with stage 4 CKD as they are in stage 3 CKD. The data support the conclusion that Rayaldee effectively controls SHPT through the correction of vitamin D insufficiency irrespective of CKD severity.

OPKO's poster presentation is entitled: "Modified-Release Calcifediol Is Effective for SHPT in Both Stages 3 and 4 CKD."

Session details: March 27-28, No. 156; Category: CKD/ESRD-Mineral Metabolism and Kidney Stones.

About Rayaldee™
Rayaldee is a first-in-class oral vitamin D prohormone treatment being developed for SHPT in patients with stage 3 or 4 CKD and vitamin D insufficiency. It has a proprietary modified-release formulation designed to gradually and reliably raise serum total 25-hydroxyvitamin D (prohormone) concentrations to targeted levels (at least 30 ng/mL) while avoiding upregulation of CYP24, a cytochrome P-450 enzyme that reduces the parathyroid hormone (PTH)-lowering potency of current vitamin D supplements. Activation of calcifediol, the active ingredient in Rayaldee, by the kidney is tightly regulated, preventing excessive elevation of serum calcium and related side effects which limit the value of current vitamin D hormone therapies by promoting vascular and renal calcification. Rayaldee is expected to address the approximately 8 million patients in the U.S., and many more elsewhere, with stage 3 or 4 CKD, SHPT and vitamin D insufficiency.

About Chronic Kidney Disease
CKD is a condition characterized by a progressive decline in kidney function. The kidney is normally responsible for excreting waste and excess water from the body, and for regulating various hormones. CKD is classified in five different stages — mild (stage 1) to severe (stage 5) disease — as measured by the kidney's glomerular filtration rate. According to the National Kidney Foundation, CKD afflicts over 26 million people in the U.S., including more than 20 million patients with moderate (stages 3 or 4) and severe (stage 5) forms of CKD. In stage 5 CKD, kidney function is minimal to absent and patients require regular dialysis or a kidney transplant for survival.

About Vitamin D Insufficiency
Vitamin D insufficiency is a condition in which the body has low vitamin D stores, characterized by inadequate blood levels of vitamin D prohormone, known as 25-hydroxyvitamin D. An estimated 70-90% of CKD patients have vitamin D insufficiency, which can lead to SHPT and resultant debilitating bone diseases. Vitamin D insufficiency has been associated with increased mortality in CKD.

About Secondary Hyperparathyroidism (SHPT)
SHPT is a condition commonly associated with CKD in which the parathyroid glands secrete excessive amounts of PTH. SHPT arises as a result of vitamin D insufficiency or impaired kidney function that prevents sufficient production of vitamin D hormone to properly regulate calcium and phosphorus metabolism, and PTH secretion. Prolonged elevation of blood PTH causes excessive calcium and phosphorus to be released from bone, leading to elevated serum calcium and phosphorus, softening of the bones (osteomalacia) and calcification of vascular and renal tissues. SHPT affects 40-60% of patients with moderate CKD and approximately 90% of patients with severe CKD. Vitamin D therapy for SHPT is associated with reduced mortality in CKD patients.

About OPKO
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. For more information, visit http://www.opko.com.

OPKO Health, Inc.
Charles Bishop, 305-575-4100

Source: OPKO Health, Inc.

News Provided by Acquire Media

 
     
     
 
   

© 2018 OPKO Health Inc.- All rights reserved. | Privacy Policy | Terms Of Use